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80 Poster Session Ireversible encephalopathy syndrome within 50 days post transplan-
tation, all of them showed complete clinical and radiological resolu-
tion. Conclusion: Non-myeloablative HSCT using this
conditioning regimen for high risk pediatric patients with benign
hematological disorders appears to be promising and worth further
study.214
PERICARDIAL EFFUSION (PEF) IS A MAJOR INDEPENDENT RISK FACTOR
ASSOCIATED WITH A SIGNIFICANT DECREASE IN SURVIVAL IN PEDIAT-
RIC STEM CELL TRANSPLANTATION (SCT) RECIPIENTS
Neier, M., Bhatia, M., Baldinger, L., Silver, E., Morris, E., van de
Ven, C., Kleinman, C., Jin, Z.Z., Cairo, M.S. Columbia University,
New York, NY.
Background: SCT is the treatment of choice for a variety of pe-
diatric conditions. Potential post SCT morbidities include cardiac
toxicity. Rhodes et al (BMT 2005) reported that PEF was seen in
4.4% of pediatric SCT recipients. Risk factors for the development
of PEF have been thought to include GVHD, infection and/or un-
derlying disease. There is a paucity of information regarding the eti-
ology, prognosis, treatment and outcome of PEF in a large cohort of
pediatric SCT recipients.Objectives: To assess the incidence, risk
factors, outcome of PEF and the impact of PEF on overall survival
(OS) in pediatric SCT recipients.Method: Echocardiograms were
performed at baseline prior to 200 SCT (4 were ineligible for re-
view) in 156 patients and when patients had symptoms and/or signs
of cardiac or pericardial disease post SCT. Probability of and time
to PEFwere analyzed by Kaplan-Meier method and risk of PEF and
deathwere determined bymultivariate analysis. Covariates included
age, gender, ethnicity, conditioning regimen, risk status (CIBMTR
criteria), conditioning regimen, donor source, CMV status,
GVHD, and HLA match. Results: The mean age was 8.15 years
(1/- 6.25 years) with 88 males and 68 females. 102 patients received
allogeneic transplants, 34 of them received more than 1 transplant.
116 of 156 recipients had malignant disease. 100 of 156 patients had
ablative conditioning. The incidence of PEF was 14.7%. A multi-
variate analysis shows that older age, poor risk and unrelated cord
blood donor recipients are significantly associated with a risk of de-
veloping PEF with hazard ratios of 1.125 (1.051–1.205), 3.508
(1.502–8.191), and 5.080 (1.141–22.625), respectively. OS was sig-
nificantly decreased in patients with PEF versus without PEF (haz-
ard ratio 5 4.84, 95% CI, 2.814–8.322, p\0.0001). Furthermore,
in a multivariate analysis, there was a significant decrease in OS as-
sociated with PEF, CMV status and poor risk status with hazard ra-
tios of 3.296 (1.73–6.26), 1.89 (1.08–3.30) and 1.93 (1.12–3.3),
respectively. Conclusion: These results demonstrate an almost
15% incidence of PEF in pediatric SCT recipients. Older, poor
risk and UCB donor recipients may be at higher risk of developing
PEF. PEFwas associatedwith themost significant impact on overall
mortality independent of other risk factors. Improved prevention
and therapeutic strategies for development of PEF in post allo
SCT recipients may potentially reduce mortality in the future.215
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN WISKOTT
ALDRICH SYNDROME (WAS): A SINGLE CENTER EXPERIENCE IN 25 PA-
TIENTS
Bonfim, C.M.S., Koliski, A., Bitencourt, M.A., Quiroga, M.,
Setubal, D.C., Funke, V., Ruiz, J., Medeiros, L., Oliveira, M.,
Coutinho, E., Zanis Neto, J., de Medeiros, C.R., Pasquini, R. Federal
University of Parana, Curitiba, PR, Brazil.
WAS is a rare X-linked disease characterized by eczema, micro-
thrombocytopenia, recurrent infections, autoimmune complica-
tions and malignancies. The gene responsible for WAS has been
identified and termed WASP. Without a successful HSCT, the
prognosis of classical WAS with a complete absence of WASP ex-
pression is poor. In this report we analyze the outcome of 25 pts
transplanted in a single center in a developing country.Material and Methods: Period: 04/92–02/07; age:1–14 ys-
old(M:2 ys). Eight pts received bone marrow(BM) from HLA
matched (5 pts) or mismatched family donors(3 pts). 17 pts received
an unrelated cord blood(URD CB). Preparatory regimen: Busul-
fan(BU)16 mg/kg1Cyclophosphamide 120–200 mg/kg in 24 pts
or BU8 mg/kg 1 Fludarabine 125 mg/m2:1 pt. ATG(rabbit) was
added to patients transplanted from unrelated donors or mis-
matched family donors. GVHD prophylaxis: Cyclosporine(Csa)1
MTX:16 pts; Csa 1 steroids:8 pts and Csa 1 MMF:1 pt. After
2005, all pts submitted to an URD CB transplantation, received
Csa1MTX as GVHD prophylaxis if the TNC infused was . 3.0
 10*7/kg. Results: 21 pts(84%) are alive between 100 – 4745
days (M:790 d) after HSCT. All pts survived more than 28 days
and were evaluable for engraftment. Primary graft failure (PGF) oc-
curred in 2 pts (both URD CB 4/6) and one pt was submitted to
a successful 2nd transplant. Most pts tolerated the procedure very
well. See table below for transplant related complications.23/25
pts were analyzed for chimerism (VNTR). 13 pts had a complete
chimerism. Ten pts were mixed chimeras immediately after
HSCT and, later on, 3 pts became full chimeras. Four pts had auto-
immune complications after transplant: 3 pts had idiopathic throm-
bocytopenic purpura(ITP) and one pt had severe auto immune
hemolytic anemia (AIHA). Frequent viral infections (CMV, EBV,
adenovirus) occurred in pts submitted to URD CB transplants. 2/
21 surviving pts have permanent sequels from neurological viral in-
fections. Conclusions: The excellent survival in this group of pts
confirms the efficacy of HSCT in this disease. Pts receiving
HSCT from 4/6 URDCB have a lower survival. Reactivation of vi-
ral infections were frequent complications in our pts and should be
monitored closely.
Post-transplant complications
URD CB BM from BM fromCompatibility:
6/6 or 5/6
N 5 11 ptsURD CB
Compatibility:
4/6 N 5 6 ptsmatched family
donors
N 5 5 ptsmismatched
family donors
N 5 3 ptsGraft failure 0 2 0 0Acute GVHD
grade III-IV3/11 1/4 0 0Chronic GVHD
extensive2/11 1/4 0 0Mixed chimeras 3 pts 2 pts 2 pts 0Auto immune
complications0 2 pts (ITP
and AIHA)1 pt (ITP) 1 pt (ITP)Overall Survival 91% 66% 80% 100%Causes of death 1 pt: D 1
1825:
bronchopneumonia
1 respiratory
failure2 pts: D 1 34 :
PGF1 fungal
infection and
D 1 132 :
C-GVHD 1
bacterial sepsis1 pt:D 1 62:
CMV pneumonia
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IRON OVERLOAD IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANS-
PLANT (HSCT) PATIENTS
Barry, E.V.1,2, Chirnomas, D.1,2, Barry, K.2, Duncan, C.N.1,2,
Lehmann, L.1,2. 1Dana-Farber Cancer Institute, Boston, MA; 2Chil-
dren’s Hospital Boston, Boston, MA.
Background: Iron can be a highly toxic molecule to cells and tis-
sues when it interacts with oxygen and generates free radicals. Free
iron, ferritin and transferrin saturation have been shown to increase
acutely in HSCT patients, and high ferritin levels can persist for
years following HSCT. The prevalence of iron overload has not
been defined in this population, and currently, no management
guidelines exist. We describe a group of pediatric HSCT patients
who were diagnosed with iron overload after developing liver func-
tion abnormalities and/or hyper-ferritinemia. Methods: We per-
formed a detailed retrospective review of patients identified as
having iron overload following allogeneic HSCT performed be-
tween 2001–2007. We included a subset of patients with known
Poster Session I 81iron overload pre-HSCT who required aggressive iron manage-
ment post-HSCT. Liver iron concentration (LIC), a surrogate of
total body iron burden, was assessed by liver biopsy and/ormagnetic
reasonance imaging (T2* or R2 MRI). Abnormal LIC was defined
as .1.5 mg iron/g dry liver tissue. Results: Patient characteristics
are presented in Table 1. 7 out of the 11 patients identified were
not previously known to have iron overload. The majority of these
patients presented with elevations in liver transaminases as the pri-
mary sign of excess iron. Liver biopsy and/or MRI were used to di-
agnose iron overload, and in all cases MRI was the method used to
assess the change in iron burden while patients were receiving ther-
apy. Most patients were managed with phlebotomy (range: 4–10 cc/
kg of blood removed every 2–4 weeks). Phlebotomy was effective in
reducing iron burden as evidenced by normalization of transami-
nases and decrease in LIC and ferritin. One patient, managed
with an oral iron chelator, did not have a reduction of overall iron
burden. Conclusions: . Iron overload should be considered in
HSCTpatients presenting with abnormal transaminases and/or hy-
perferritinemia after transplant. MRI is a useful diagnostic tool and
may obviate the need for invasive liver biopsy. Phlebotomy appears
to be effective in reducing iron burden, however the safety and effi-
cacy of chelators is not yet established. There is a need for prospec-
tive studies to define the prevalence of iron overload, establish
guidelines for screening, and develop safe and effective therapies.
As a result, we have initiated a prospective study using R2 MRI to
determine the incidence and morbidity associated with iron over-
load in this patient population.
Characteristics of Patients With Iron Overload
Condition LIC pre/postNumber Diagnosis, Age
Type of
HSCT
tLeading
o Iron Overload
Diagnosis oManagment
f Iron Overloadtreatment
(mg iron/g
liver)
mALT
ax/min
(u/L)Ferritin
max/min
(ng/mL)1 Relapsed
ALL, 1 yoMURD Abnormal LFT’s Phlebotomy 7.3/4.0 254/38 2,896/4492 PNH, 18 yo MURD Abnormal LFT’s Desferasirox 10.7/13.6 910/56 5,127/2,5273 Relapsed
ALL, 6 yoMURD Abnormal LFT’s Phlebotomy 5.1/1.9 404/57 4,071/7964 Relapsed
ALL, 10 yoMURD Abnormal LFT’s Phlebotomy 16.0/– 314/53 5,586/2,3505 Sickle
Cell Anemia, 9 yoMRD Abnormal LFT’s Phlebotomy
planned4.9/– 313/– 1,810/–6 AML, 4 yo MRD Hyperferritinemia Phlebotomy
planned5.1/– 70/– 1,938/–7 ALL, 12 yo 4/6 Cord Abnormal LFT’s Phlebotomy
planned13.0/– 209/– 3,645/–8 Diamond-
Blackfan
Anemia, 9 yoMRD Chronic
transfusion
historyPhlebotomy 17.5/0.9 13/4 1,029/1199 Aplastic
Anemia, 6 yoMRD Chronic
transfusion
historyPhlebotomy 22.5/– 35/20 4,574/2,82410 Beta-
thalassemia,
8 yoMRD Chronic
transfusion
historyPhlebotomy 7.0/– 38/31 3,900/65811 Beta-
thalassemia,
7 yoMRD Chronic
transfusion
historyPhlebotomy
planned8.6/– 94/41 1,888/–Abbreviations: PNH 5 Paroxysmal Nocturnal Hemoglobinuria,
ALL5Acute Lymphoblastic Leukemia, AML5AcuteMyeloid
Leukemia, MURD 5 Matched Unrelated Donor, MRD 5
Matched Related Donor, ALT 5 Alanine Aminotransferase.
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CHALLENGES IN THE USE OF HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION FOR ECTODERMAL DYSPLASIA WITH IMMUNE DEFICIENCY
Fish, J.D.1, Duerst, R.E.2, Gelfand, E.W.3, Orange, J.4, Bunin, N.1.
1The Children’s Hospital of Philadelphia, Philadelphia, PA; 2Children’s
Memorial Hospital, Chicago, IL; 3National Jewish Medical and ResearchCenter, Denver, CO; 4The Children’s Hospital of Philadelphia, Philadel-
phia, PA.
Genetic mutations affecting regulatory proteins of NF-kB result
in heritable diseases of development and immunity. Hypomorphic,
X-linked mutations in the IKBKG gene (NEMO protein), and hy-
permorphic, autosomal dominant mutations in the IKBA gene
(IkBa protein), are associated with a phenotype of ectodermal dys-
plasia with immune deficiency (ED-ID). ED-ID predisposes pa-
tients to bacterial and mycobacterial infections, and is typically
fatal. Allogeneic HSCT may correct the immune deficiency associ-
ated with NEMO or IkBamutations, but there are few reports. We
report 3 patients with ED-ID who underwent HSCT. All patients
experienced engraftment difficulties. Patient 1 presented with fe-
vers, diarrhea, diffuse erythema and desquamation. Hypogamma-
globulinemia with normal B- and T- cell numbers and subsets
were noted, and genetic analysis revealed a hypomorphic NEMO
mutation. He received matched sibling donor peripheral blood
stem cells (PBSC) at 6 months following reduced-intensity condi-
tioning with fludarabine, busulfan and ALG. Neutrophil engraft-
ment was achieved at day 117, and maximal donor T-cell
chimerism of 53% at day 177, which then declined. A second
PBSCT from the same donor was undertaken after conditioning
with alemtuzumab, fludarabine and melphalan, with stable donor
chimerism through day1310. Patient 2 developed diarrhea, failure
to thrive and recurrent infections including MAI. Inadequate anti-
body responses, but normal B- and T- cell numbers and subsets
were noted. Genetic analysis demonstrated a hypomorphic
NEMO mutation. A MUD BMT was performed at 3 years of age
following myeloablative conditioning with busulfan, cyclophospha-
mide and ALG. Poor engraftment was noted, with persistent neu-
tropenia despite chimerism of 95% donor at day 138. The
patient was re-conditioned with fludarabine, and a CD34-selected
PBSC boost from the same donor. Although complete chimerism
was achieved, the patient remained pancytopenic and died at day
1314 of gram-negative infection. Patient 3 presented with recur-
rent bacterial infections, p.carinii, and chronic diarrhea. Genetic
analysis confirmed an IkBa mutation. The patient underwent
a MUD cord blood transplant following myeloablative condition-
ing with busulfan and cyclophosphamide, but expired from sepsis
prior to engraftment. These cases suggest that patients with im-
mune deficiencies caused by NEMO or IkBa mutations may have
intrinsic barriers to successful engraftment, which require further
investigation.
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LOWER LEUKEMIA RELAPSE IN PATIENTS WITH PULMONARY CYTO-
LYTIC THROMBI AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANS-
PLANT
Verneris, M.R.1, Gulbahce, E.2, Burke, M.1, Cao, Q.1,
MacMillan, M.L.1, Tolar, J.1, Orchard, P.1, Blazar, B.R.1, Baker, S.1,
Wagner, J.E.1. 1University of Minnesota, Minneapolis, MN; 2Univer-
sity of Minnesota, Minneapolis, MN.
Pulmonary cytolytic thrombi (PCT) is an uncommon post-trans-
plant complication, which is more commonly reported in children
than adults. PCT typically presents with low grade fever, cough,
shortness of breath and/or hypoxia. Lung CT findings range from
small, peripheral nodules to large diffuse infiltrates. The diagnosis
is established by lung biopsy, which reveals areas of the pulmonary
vasculature which are occluded with cellular debris. Bronchoscopy
and lung biopsy are negative for infectious organisms by both im-
muno-stains and culture.While the pathogenesis of PCT is not cur-
rently known, it has been previously shown that patients with PCT
frequently have concurrent aGVHD and that PCT responds to sys-
temic corticosteroid treatment. Considering that such treatment
may impair graft vs. leukemia (GVL) reactions, we investigated
the outcome of patients who developed PCT after transplantation
for hematological malignancy. From 1993–2006, we identified 14
pediatric patients with biopsy proven PCT and a hematological ma-
lignancy (9 ALL, 3 AML and 2 CML). PCTwas diagnosed at an av-
erage of 901/-38 days (range 38–342) after transplant. We
compared outcomes to a cohort of pediatric leukemia patients
that not develop PCT, but were transplanted during the same
time interval (n 5 323). There were no significant differences
